Compare Enveric Biosciences Inc (ENVB) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Consumer Discretionary Select Sector SPDR Fund trades at $119.22. The key difference: Consumer Discretionary Select Sector SPDR Fund is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | XLY | |
|---|---|---|
Market Cap | $6.20M | — |
Sector | Health | — |
52-Week High | $17.40 | $124.52 |
52-Week Low | $1.27 | $105.64 |
Enterprise Value | $1.30M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
XLY trades at $119.86, up 1.47% with strong bullish technical momentum indicated by moving averages. Analyst consensus is unanimously positive with 100% buy ratings. The consumer discretionary ETF shows resilience amid economic uncertainty, with recent news highlighting its potential as a 'sleeper ETF' for Q3 2026. Technical indicators show overbought conditions on short-term RSI but strong trend momentum on ADX readings.
XLY presents a bullish case with strong technical momentum and unanimous analyst support, though current RSI levels suggest potential near-term consolidation. The ETF's performance hinges on consumer discretionary spending trends amid evolving inflation dynamics. Key risks include consumer confidence erosion and broader economic pressures affecting discretionary purchases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
